SeaStar Medical is a medical technology company focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or Twitter.
Company profile
Ticker
ICU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LMF Acquisition Opportunities Inc
SEC CIK
Corporate docs
IRS number
853681132
ICU stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
18 Apr 24
8-K
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
17 Apr 24
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K/A
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
27 Mar 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
27 Mar 24
8-K
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
27 Mar 24
8-K
Other Events
8 Mar 24
424B3
Prospectus supplement
5 Mar 24
424B3
Prospectus supplement
5 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 73.00 k | 73.00 k | 73.00 k | 73.00 k | 73.00 k | 73.00 k |
Cash burn (monthly) | (no burn) | (no burn) | 2.48 mm | (no burn) | 445.67 k | 925.17 k |
Cash used (since last report) | n/a | n/a | 16.80 mm | n/a | 3.02 mm | 6.28 mm |
Cash remaining | n/a | n/a | -16.73 mm | n/a | -2.95 mm | -6.21 mm |
Runway (months of cash) | n/a | n/a | -6.8 | n/a | -6.6 | -6.7 |
Institutional ownership, Q4 2023
11.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 17 |
Closed positions | 31 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 275.24 mm |
Total shares | 8.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
LMFAO Sponsor | 8.33 mm | $0.00 |
Vanguard | 261.67 k | $115.84 mm |
STT State Street | 59.40 k | $26.30 mm |
MS Morgan Stanley | 50.00 k | $22.14 mm |
EQH Equitable | 50.00 k | $22.14 mm |
SFMG | 43.89 k | $19.43 mm |
Perigon Wealth Management | 34.35 k | $15.21 mm |
OMERS ADMINISTRATION | 33.80 k | $14.96 mm |
Thoroughbred Financial Services | 25.83 k | $11.00 k |
Jane Street | 17.08 k | $7.56 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Apr 24 | Rodgers Bruce M. | Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 0 | 36,537 | 0.00 | 44,515 |
12 Apr 24 | Allan Collins | Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 0 | 37,943 | 0.00 | 54,343 |
12 Apr 24 | Heel Kenneth Van | Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 0 | 43,564 | 0.00 | 159,964 |
12 Apr 24 | Rick Barnett | Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 0 | 70,264 | 0.00 | 86,664 |
12 Apr 24 | Andres Lobo | Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 0 | 32,322 | 0.00 | 40,300 |
News
12 Health Care Stocks Moving In Friday's Intraday Session
19 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
18 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Apr 24
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
18 Apr 24
SeaStar Medical Holding Q4 EPS $(0.19) Misses $(0.13) Estimate
17 Apr 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
20 Apr 24
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
17 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
16 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
12 Apr 24
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference
11 Apr 24